Hanmi Pharm Signs 52.7 Billion KRW, 10-Year Supply Contract with Organon for 3 CV/Respiratory Drugs
- Hanmi Pharm (subsidiary of Hanmi Science) signed a supply contract with Organon International GmbH for 3 cardiovascular/respiratory drugs, total contract value of 52.74 billion KRW (including milestones and 10-year estimated sales).
- Territory includes Philippines and Malaysia; contract period is 10 years from local launch (expected start 2026-05-18).
- Contract value corresponds to 3.4% of Hanmi Pharm's 2025 consolidated revenue (1.5475 trillion KRW).
- Two products already approved in Philippines; remaining products subject to local regulatory approvals.
ADVERTISEMENT (250px+)
KOSPI Filing Information
- Filing: Conclusion of Single Sales/Supply Contract (Major Management Matters of Subsidiary)
- Company: Hanmi Science (008930)
- Submission: Hanmi Science Co.,Ltd
- Receipt: 05-21-2026
- Under KRX KOSPI Market Division